YTX-7739 Works to Block SCD Enzyme at Well-Tolerated Doses, Yumanity Says
Dose-dependent decreases in targeted fatty acids were seen with YTX-7739, an investigational therapy for Parkinson’s disease, suggesting the medicine engages its therapeutic target, according to the results of a Phase 1a multiple-ascending dose study in healthy volunteers.